Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC01009 in Severe Viral Pneumonia
NCT06693362Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SC01009 in viral pneumonia (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 24 weeks, Infusion reactions at Day 5 and 5 more. Started Jan 2025; status: recruiting.
02
Drugs
SC01009
03
Conditions
viral pneumonia
Beyond the preview
Go deeper on NCT06693362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693362.